Immuneering annual r&d spending
2020
2021
2022
2023
2024
2025
Immuneering R&D Spending Growth & History (IMRX)
Immuneering's r&d spending was $42.0M for fiscal 2025.
View full Immuneering company overviewImmuneering annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $42.0M | −$5.9M | −12.33% |
| 2024 | 2024-12-31 | $48.0M | $6.3M | +15.23% |
| 2023 | 2023-12-31 | $41.6M | $5.4M | +14.77% |
| 2022 | 2022-12-31 | $36.3M | $9.7M | +36.65% |
| 2021 | 2021-12-31 | $26.5M | $11.5M | +76.90% |
| 2020 | 2020-12-31 | $15.0M | — | — |
Immuneering quarterly r&d spending
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $14.0M | $3.5M | +33.89% |
| Q1 2026 | 2026-03-31 | $10.6M | −$826,471 | −7.20% |
| Q4 2025 | 2025-12-31 | $9.3M | −$5.6M | −37.71% |
| Q3 2025 | 2025-09-30 | $10.9M | −$384,867 | −3.42% |
| Q2 2025 | 2025-06-30 | $10.5M | −$197,798 | −1.86% |
| Q1 2025 | 2025-03-31 | $11.5M | $269,279 | +2.40% |
| Q4 2024 | 2024-12-31 | $14.9M | $2.9M | +24.74% |
| Q3 2024 | 2024-09-30 | $11.3M | $1.2M | +11.97% |
| Q2 2024 | 2024-06-30 | $10.7M | $1.2M | +12.69% |
| Q1 2024 | 2024-03-31 | $11.2M | $991,488 | +9.71% |
| Q4 2023 | 2023-12-31 | $11.9M | $2.0M | +20.75% |
| Q3 2023 | 2023-09-30 | $10.1M | $686,360 | +7.33% |
| Q2 2023 | 2023-06-30 | $9.5M | $1.5M | +18.44% |
| Q1 2023 | 2023-03-31 | $10.2M | $1.2M | +12.72% |
| Q4 2022 | 2022-12-31 | $9.9M | $1.9M | +24.06% |
| Q3 2022 | 2022-09-30 | $9.4M | $3.2M | +50.85% |
| Q2 2022 | 2022-06-30 | $8.0M | $989,110 | +14.15% |
| Q1 2022 | 2022-03-31 | $9.1M | $3.7M | +68.03% |
| Q4 2021 | 2021-12-31 | $8.0M | — | — |
| Q3 2021 | 2021-09-30 | $6.2M | $2.1M | +52.55% |
| Q2 2021 | 2021-06-30 | $7.0M | $3.8M | +117.07% |
| Q1 2021 | 2021-03-31 | $5.4M | — | — |
| Q3 2020 | 2020-09-30 | $4.1M | — | — |
| Q2 2020 | 2020-06-30 | $3.2M | — | — |
Immuneering r&d spending trends
Over the last five fiscal years, Immuneering's r&d spending increased from $15.0M to $42.0M, a change of $27.0M. The latest reported quarter, Q2 2026, shows $14.0M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immuneering source filings ↗